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Sickle cell anemia patients have 600 times the risk for
invasive pneumococcal disease than their healthy peers.
High-level cephalosporin resistance was described in the
1990s in healthy children from Tennessee, but its preva-
lence in sickle cell disease patients is unknown.
Pneumococcal isolates from sickle cell disease patients
from Tennessee were subjected to multilocus sequence
typing to characterize antimicrobial drug–resistant strains.
Twenty-one percent of strains were resistant to cefotaxime
and penicillin. Of the 14 cephalosporin-resistant strains, 9
were sequence types previously described as highly
cephalosporin resistant, while resistance was found for the
first time in 3 clones: Maryland6B, ST660, and a novel
clone, ST1753. High-level cephalosporin resistance exists
in more settings than initially recognized, and its high
prevalence in sickle cell disease patients may decrease the
efficacy of third-generation cephalosporins in invasive
pneumococcal disease.
S
treptococcus pneumoniae is a gram-positive bacterium
that causes substantial illness and death in children.
Children with sickle cell disease have an increased risk for
invasive infection from this pathogen. Before the routine
use of prophylactic measures, invasive pneumococcal dis-
ease was 600 times more likely to develop in patients with
sickle cell disease than in their healthy peers (1). Thus, col-
onization with pneumococci is viewed as a high-risk event
for sickle cell disease patients.
The risk for fatal infection increases if the patient is col-
onized with antimicrobial drug–resistant pneumococci.
The prevalence of colonization with pneumococci is gen-
erally the same in healthy persons (12%) and sickle cell
disease patients (7%) (2). However, penicillin-resistant
pneumococci are consistently more common in children
with sickle cell disease (62% versus 41% in healthy chil-
dren) (2). A similarly high incidence of penicillin resist-
ance (55%) in pneumococci infecting sickle cell disease
patients was reported by Daw et al. (3) and has been sus-
tained throughout the 1990s (4).
In the early 1990s, the Centers for Disease Control and
Prevention described a series of community-acquired inva-
sive infections in healthy children from Memphis,
Tennessee, caused by pneumococci with unusually high
resistance to extended-spectrum cephalosporins (5). These
strains displayed MICs of cefotaxime and ceftriaxone from
4 to 32 µg/mL, exceeding the MICs of penicillin by as
much as 5-fold (6). This finding is of clinical importance
since it precludes using cephalosporins as a treatment
option (6,7). Richter et al. extended the analysis of this
resistant Tennessee cluster and identified a novel clone
termed TN23F-4 with MIC values of third-generation
cephalosporins as high as 32 µg/mL (8,9).
The epidemiology of the cephalosporin-resistant TN23F-
4 clone in sickle cell disease patients is unknown.
Colonization with this clone would have implications in
terms of drug therapy, since this patient population rou-
tinely receives standard doses of extended-spectrum
cephalosporins to treat invasive pneumococcal disease.
Infection with a strain exhibiting high-level cephalosporin-
resistance could result in treatment failure. In this study,
we reexamined pneumococci collected from sickle cell
disease patients in Memphis, Tennessee, from 1994 to
1995, the time of the original description of the TN23F-4
clone, to determine the prevalence of this clone and any
other highly cephalosporin-resistant clones circulating in
the sickle cell disease population.
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Pneumococcal Strains
Sixty-four nasopharyngeal isolates were collected from
42 patients between July 1994 and December 1995 at the
Mid-South Sickle Cell Center (3). Frozen strains were
recovered by overnight growth on blood agar plates at
37°C, followed by resuspension in 15% glycerol solution.
Strains were refrozen at –80°C for further use. Since this
study was retrospective and used clinical pneumococcal
strains, institutional review board permission was granted
to review characteristics specific to the isolates themselves.
Limited patient demographics were obtained, including
patient diagnosis and penicillin prophylaxis. Antimicrobial
susceptibility testing was conducted as described (3).
Susceptibility breakpoints were defined according to the
Clinical and Laboratory Standards Institute (formerly
NCCLS) guidelines for the years 1994 and 1995 (10,11).
Pneumococcal isolates were serotyped by the slide aggluti-
nation method (12) with the Pneumotest-Latex Kit (Statens
Serum Institut, Copenhagen, Denmark).
Genomic DNA Preparation
Genomic DNAwas prepared by sodium dodecyl sulfate
(SDS) lysis (13) and standard phenol:chloroform extrac-
tion (14). Each strain was grown in 20 mL casein/yeast
broth (15) at 37°C in 5% CO2 until turbid. Bacteria were
harvested by centrifugation; resuspended in 500 µL (1:20
volume) iced buffer containing Tris-HCl, glucose, and
EDTA(13); and treated with 15 µL 10% deoxycholate and
1.25 µL10% SDS. After incubation at 37°C for 30 min, 30
µL 10% SDS was added and gently mixed by inversion.
The mixture was incubated with 200 µg/mL proteinase K
(Invitrogen, Carlsbad, CA, USA) overnight. An equal vol-
ume of phenol:chloroform:isoamyl (Invitrogen) was added
to each sample and centrifuged for 5 min at 12,000 rpm.
The upper phase was treated 2 more times. The extract was
treated with 10% volume of 3 mol/L sodium acetate. DNA
was then precipitated by adding 2 volumes of cold
95%–100% ethanol. The DNA pellet was treated twice
with cold 70% alcohol. The resultant sample was air dried
and resuspended in 20 µL distilled water.
Multilocus Sequence Typing
To assign the strains to a sequence type (ST), 7 house-
keeping genes were subjected to polymerase chain reac-
tion (PCR) amplification and DNAnucleotide sequencing:
aroE (shikimate dehydrogenase), gdh (glucose 6-phos-
phate dehydrogenase), gki (glucose kinase), recP (transke-
tolase),  spi (signal peptidase I), xpt (xanthine
phosphoribosyltransferase), and ddl (D-alanine-D-alanine
ligase). The primer sets were obtained from the multilocus
sequence typing (MLST) Web site (www.mlst.net). Fifty-
microliter reaction mixtures were prepared with 1.25 U
Taq polymerase (Applied Biosystems, Foster City, CA,
USA), 1× Taq polymerase buffer (10 mmol/L Tris-HCl
[pH 8.3], 50 mmol/LKCl), 1.5 mmol/LMgCl, 0.2 mmol/L
each deoxynucleoside triphosphate, and 0.2 mmol/L each
primer. One microliter of genomic DNAwas added to each
reaction. The following parameters were used for amplifi-
cation: denaturation at 95°C for 5 min, 30 subsequent
cycles of amplification, each consisting of 1 min at 95°C,
1 min at 50°C, and 30 s at 72°C, with a final extension at
72°C for 7 min. PCR products were analyzed by elec-
trophoresis on a 1.0% wt/vol agarose gel, and the amplicon
size was evaluated by comparing it with 1-kb ladder
(Invitrogen). PCR products were purified by using the
QIAquick PCR purification kit (Qiagen, Valencia, CA,
USA). Sequencing, with forward and reverse primers, was
performed on the ABI 377 DNA sequencer with Big Dye
chemistry (Applied Biosystems), according to ABI proto-
cols, by the St. Jude Hartwell Center for Bioinformatics
and Biotechnology. 
Phylogenetic Analysis
Sequencing results were assembled by using SeqAssem
version 09/2004 (http://www.gwdg.de/~dhepper/).
Sequences were subsequently queried against the NCBI
nonredundant database by using both nucleotide-BLAST
[blastn] and protein-BLAST [blastp] programs and com-
pared by alignment with the ClustalW algorithm in
BioEdit (16). Concatenated DNA alignments of the 7
housekeeping genes were used for phylogenetic analysis.
The phylogenetic relationship among the 64 pneumococ-
cal strains was inferred by using the Bayesian approach
(17), a variant of the maximum likelihood algorithm.
Although eBURST (18,19) defines clonality based on 6/7
shared alleles, the Bayesian approach allows resolution of
clonality based on 7/7 alleles. Thus, the Bayesian approach
allows branch placement, due to differing alleles, into a
paraphyletic clade versus clustering as a monophyletic
clade. Clade credibility for the consensus tree topology
was calculated by using MrBayes version 3.0b4 (20) with
the following parameters: 1 million generations, 4 simulta-
neous Monte Carlo chains, and exclusion of the first 1,000
trees. The tree was rooted by using data from the S. pneu-
moniae TIGR4 strain (21) as an outgroup. An evolutionary
model of nucleotide substitution was selected by using the
MrModeltest program version 2.1 (22).
Results
We analyzed 64 nasopharyngeal strains from patients in
whom homozygous sickle cell disease (HgbSS), hemoglo-
bin SC sickle cell disease (HgbSC), or hemoglobin Sβ+ tha-
lassemia (HgbSβ+) was diagnosed. Antimicrobial
drug–susceptibility results are represented in Tables 1 and 2.
Cephalosporin-resistant Pneumococci and Sickle Cell Disease
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 8, August 2005 1193Fifty-one percent (33/64) of the strains were penicillin-
resistant (intermediate strains included). Of these strains,
14 (42%) of 33 were resistant to cefotaxime. No serotypes
consistently correlated with antimicrobial drug resistance
(Table 2).
All strains were subjected to MLST and phylogenetic
analysis (Table 2, Figure). Isolates were designated as
novel if they possessed >1 unrecognized alleles based
upon known sequences listed in the MLST database.
Isolates were designated as nontypeable (NT) if the allele
profile was not listed in the MLST database. The 31 peni-
cillin-sensitive strains were distributed broadly through 19
known STs (13, 43, 62, 124, 146, 176, 180, 205, 208, 425,
433, 439, 447, 547, 647, 690, 876, 899, and 1499), 2 puta-
tive novel strains (1752 and pending ST), and 3 NT strains
(1755 and 1757). Intermediate penicillin resistance (n =
24) was also broadly represented by 8 known STs (37, 199,
236, 344, 384, 460, 660, and 690), 4 novel STs (1754 and
3 distinct STs with pending designations), and 2 NT
sequence types (1756 and pending ST referred to as NT3)
(Table 2).
In contrast to the broad ST distribution of sensitive
and intermediate penicillin-resistant strains, high-level
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STs (37, 67, 384, and the novel 1753). Two of these STs
have been reported previously to be highly cephalosporin
resistant: TN23F-4 (ST37) and TN14-18 (ST67) (23). Five
(8%) of 64 strains were classified as the TN23F-4 clone, all
of which were highly resistant, and 4 (6%) were designat-
ed as TN14-18; 1 of these was highly resistant and 3 were
intermediate. Two STs, Maryland6B-17 (ST384) and
Taiwan19F-14 (ST236), have been reported to be intermedi-
ately cephalosporin resistant (24,25). In this study cohort,
1 Maryland6B-17 was highly resistant and 1 intermediate.
One of the 3 Taiwan19F-14 strains was intermediately
resistant, while the other 2 were sensitive. Seven isolates
(11%) of the study cohort represented distinct putative
novel clones (ST1752, 1753, and 1754; additional
designations from MLST database are still pending); 1 of
these isolates (ST1753) was highly cephalosporin resist-
ant. ST1753 is closely related to TN23F-4 (ST37). Two of
the newly recognized cephalosporin-resistant clones
(ST384 and 660) were not closely related to each other or
the TN clones (Figure). 
Discussion
Although the incidence of carriage of penicillin-non-
susceptible pneumococcus is highly variable, depending
on area (from <5% to <50%) (7,26), the incidence is gen-
erally increasing worldwide. Children with sickle cell dis-
ease routinely receive penicillin prophylaxis as well as
empiric therapy with third-generation cephalosporins and
have a higher rate of carriage of penicillin-resistant strains
(2–4).
We analyzed cephalosporin resistance in pneumococcal
nasopharyngeal isolates collected from 1994 to 1995 from
patients with sickle cell disease in Memphis, a time and
place corresponding to the initial description of the highly
cephalosporin-resistant TN23F-4 clone. Fifty-one percent of
strains were penicillin resistant, a percentage consistent
with that seen in many previous sickle cell disease studies
(2–4). Strikingly, 14 (21%) of 64 isolates were resistant to
cefotaxime, 12.5% at high level, and all of the
cephalosporin-resistant strains were also resistant to peni-
cillin. Although this sample is small and precludes the abil-
ity for direct comparison, this percentage is much greater
than the 4.6% reported for clone TN23F-4 (8). Nine of the
14 cephalosporin-resistant strains were either the TN23F-4
clone or TN14-18, the 2 sequence types reported previous-
ly to be highly cephalosporin resistant (5,6,23). Of the
remaining 5 cephalosporin-resistant strains, 4 STs,
Maryland6B-17 (25), Taiwan19F-14 (24), ST660, and a
novel clone ST1753, had increased levels of cephalosporin
resistance not previously described. Of these newly
described resistant strains, only the novel clone was close-
ly related to either TN clones, suggesting that high-level
third-generation cephalosporin resistance exists in a wider
array of backgrounds than previously recognized.
Fifty-three (80%) of the 66 strains had serotypes con-
tained in the Prevnar vaccine (Wyeth Pharmaceuticals,
Philadelphia, PA, USA), including all cefotaxime-resistant
strains. Routine administration of Prevnar since 2000 (5
years after these strains were collected) is likely to have
protected most of the sickle cell disease population from
risk for cephalosporin-resistant disease. However, the
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Figure. Bayesian analysis of the phylogenetic relationship among
pneumococcal isolates from sickle-cell disease patients as deter-
mined by multilocus sequence type (MLST). ST, sequence type,
as defined by the MLST database. Strains in boldface had recog-
nized allele numbers but not recognized profiles according to the
current database (listed as NT). Putative novel sequence types
(those with unrecognized alleles) are in boldface and italics. Dots
indicate resistance to penicillin. Boxes indicate sequence types
determined to be resistant to cephalosporins. Red box, intermedi-
ate resistance, previously described; black box, highly resistant,
previously described; yellow box, intermediate resistance, not pre-
viously described; white box, highly resistant, not previously
described. Clade credibility scores >80% are listed on the tree.possibility of colonization with nonvaccine serotypes or
the extension of cefotaxime resistance into previously
unrecognized backgrounds should not be underestimated.
Aggressive management is warranted to prevent death
from invasive pneumococcal infections in children with
sickle cell disease. With the increasing prevalence of peni-
cillin and extended-spectrum cephalosporin resistance in
the sickle cell disease population, alternative antimicrobial
drug therapies may be needed for prophylaxis. If the high
prevalence of third-generation cephalosporin resistance is
documented in the sickle cell disease population in other
geographic areas, extended-spectrum cephalosporins
should be reconsidered as empiric therapy when invasive
pneumococcal disease is suspected. As antimicrobial drug
alternatives are eliminated, vaccination becomes more
important as the mainstay of prophylactic management of
disease.
Dr. Miller is a third-year infectious diseases fellow at St.
Jude Children’s Research Hospital. Her research interest is
molecular epidemiology, specifically, Streptococcus pneumoniae
analysis.
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